#tempus ai

[innonurse]

Tempus to acquire Personalis in $1.5 billion deal

- By InnoNurse Staff -

Tempus AI announced a definitive agreement to acquire Personalis in an all-stock transaction valued at approximately $1.5 billion (enterprise value).

The acquisition is intended to strengthen Tempus' capabilities in molecular residual disease (MRD) testing by combining Personalis' tumor-informed MRD technology with Tempus' AI platform, multimodal data assets, and commercial infrastructure.

The companies have collaborated since 2023, when Tempus invested in Personalis and began commercializing its NeXT Personal MRD test. Tempus says the acquisition is expected to expand its presence across the cancer care continuum, from diagnosis and treatment selection to long-term monitoring and recurrence detection.

Under the agreement, Personalis shareholders will receive consideration valued at $16.25 per share, representing a 6% premium to the previous closing price and a 28% premium to the unaffected 30-day volume-weighted average price. The transaction is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory approvals, and customary closing conditions.

Tempus stated that the acquisition positions the combined company to compete in the growing MRD market, which it estimates as a $20 billion opportunity. Personalis reported preliminary Q2 revenue of $22.4 million and processed 10,384 clinical tests during the quarter, a 33% sequential increase in test volume.

The announcement also notes that the transaction involves customary risks and uncertainties, including the need for regulatory and shareholder approvals, successful integration of the businesses, and the possibility that anticipated synergies or financial benefits may not be realized.

Read more at Tempus AI/Business Wire

///

Other recent news and insights

HealthTech startup Plazza raises $15 million in Series A to expand AI-driven pharmacy network

Ukrainian healthtech startup Tayra AI has raised $500,000

Anara Impact Capital leads $1.45 Million round for Egyptian Healthtech Reme-D

[ms2253]

Legible Bio: Ep 5: Creative Destruction in Biotech with Shelby Newsad

Episode webpage: https://www.legible.bio/p/ep-5-creative-destruction-in-biotech

Ep 5: Creative Destruction in Biotech with Shelby Newsad

Consumer biotech, problem with peptides, implications of looksmaxxing

Media file: https://api.substack.com/feed/podcast/186243511/a93e7f8ff0172cfb5418034a8d08e8af.mp3

[stpauldevarces2026]

Eric Lefkofsky et les premiers doutes sur l'IA : Tempus AI a perdu 25 % en Bourse dans la dernière semaine. Cette société d'Eric Lefkofsky est pourtant l'une des plus prometteuses : l'IA appliquée à la santé.

De façon plus générale, l'IA peine à mettre en relief ses valeurs ajoutées majeures immédiates. Et surtout, ce sentiment que les

plus "gros" (Google ...) écraseront ce marché une fois les émergences affirmées. On semble loin des premières années d'Internet et la perception des "révolutions" immédiates dans la vie quotidienne du grand nombre.

[timesofupdate]

3 stocks she just bought

Cathie Wood is having a tough year as co-founder, CEO and investment manager of Ark Invest. Her largest exchange-traded fund is trading 15% lower this year, a stark contrast to a winning year for many growth investors. She’s not giving up hope. She’s been buying stocks all summer. Wood added to three existing positions on Thursday, buying more shares in Tempus AI (NASDAQ: TEM), Blade air mobility…

[innonurse]

Precision medicine company Tempus AI seeks to raise $400M in IPO

- By InnoNurse Staff -

The Chicago-based firm, known for its data and analytics tools in precision medicine, aims to generate up to $410.7 million by offering 11.1 million shares priced between $35 and $37 each, as stated in an updated prospectus filed on Wednesday.

The company is aiming for a valuation of up to $6.10 billion in its U.S. IPO.

Read more at Fierce Healthcare

///

Other recent news and insights

Eyebot strives to make vision care more accessible with AI-powered kiosks, securing $6M for expansion (Fierce Healthcare)

Canada: DIGITAL allocates $10.5 million to four AI healthtech startup projects (BetaKit)

New AI-driven statistical method promises advancements in tissue and disease research (University of Michigan)